Login to Your Account



Unmet Needs and Heterogeneity

InterMune's CRL Response Highlights Pros, Cons of IPF

By Brian Orelli


Monday, June 6, 2011
At its recent analyst day, InterMune Inc. updated investors on plans for the confirmatory trial required to obtain U.S. approval for its idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone), which the FDA slapped with a complete response letter last year.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription